1412891-40-7

1412891-40-7 structure

Name: Tenatumomab
Chemical Name: Tenatumomab
CAS Number: 1412891-40-7
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-02-03 11:10:45
Modify Date: 2024-09-14 13:36:00
Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunotherapy (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach[1][2].

Name	Tenatumomab

Description	Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunotherapy (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
Target	tenascin-C[1][2]
In Vitro	Tenascin-C 是一种在胚胎和成人细胞外基质中发现的六聚体糖蛋白，在恶性实体瘤和血液肿瘤中优先表达。Tenascin-C在空间和时间上与肿瘤新生血管相关，并可能发挥抗粘连和免疫抑制活性[2]。 Tenatumomab (2-5 μg/mL; 16 h) 生物素化后保持免疫反应性。并且每个单抗可以结合多达 20 个生物素，保持 50% 的免疫反应性[2]。
In Vivo	Tenatumomab (4 μg 每鼠; 静脉注射; 单词剂量) 在移植人 HT-29 结肠癌细胞和/或人 U-118MG 胶质母细胞瘤细胞的裸鼠中，分别显示了与低和高张力蛋白表达相关的生物分布[2]。
References	[1]. Giannini G, et al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253. [2]. De Santis R, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6.

No Any Chemical & Physical Properties